Shares of Abiomed (NASDAQ:ABMD) have been given an average rating of “Buy” by the twelve analysts that are covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation, eight have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $325.00.
ABMD has been the subject of a number of analyst reports. BidaskClub raised Abiomed from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 20th. Piper Jaffray reaffirmed a “positive” rating and issued a $300.00 price target (up previously from $220.00) on shares of Abiomed in a research note on Thursday, February 1st. Jefferies Group reaffirmed a “buy” rating and issued a $300.00 price target on shares of Abiomed in a research note on Thursday, February 1st. Guggenheim reissued a “buy” rating and set a $280.00 target price on shares of Abiomed in a research note on Friday, February 2nd. Finally, Morgan Stanley boosted their target price on Abiomed from $204.00 to $259.00 and gave the stock an “equal weight” rating in a research note on Friday, February 2nd.
Abiomed opened at $384.36 on Friday, MarketBeat Ratings reports. The stock has a market capitalization of $17.02 billion, a P/E ratio of 156.88, a P/E/G ratio of 4.15 and a beta of 0.18. Abiomed has a 52 week low of $132.63 and a 52 week high of $388.75.
Abiomed (NASDAQ:ABMD) last posted its quarterly earnings results on Thursday, May 3rd. The medical equipment provider reported $0.80 EPS for the quarter, beating the Zacks’ consensus estimate of $0.64 by $0.16. The business had revenue of $174.44 million during the quarter, compared to the consensus estimate of $164.30 million. Abiomed had a return on equity of 17.58% and a net margin of 18.89%. Abiomed’s revenue for the quarter was up 39.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.33 earnings per share. equities analysts expect that Abiomed will post 3.43 EPS for the current year.
In other Abiomed news, VP Andrew J. Greenfield sold 20,000 shares of the business’s stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $270.36, for a total transaction of $5,407,200.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Martin P. Sutter sold 21,890 shares of the business’s stock in a transaction dated Tuesday, May 8th. The stock was sold at an average price of $343.50, for a total value of $7,519,215.00. Following the transaction, the director now directly owns 46,668 shares of the company’s stock, valued at approximately $16,030,458. The disclosure for this sale can be found here. In the last three months, insiders have sold 82,180 shares of company stock valued at $26,949,944. Insiders own 7.00% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Swiss National Bank grew its holdings in shares of Abiomed by 2.4% during the fourth quarter. Swiss National Bank now owns 71,300 shares of the medical equipment provider’s stock worth $13,362,000 after purchasing an additional 1,700 shares during the last quarter. Pratt Collard Advisory Partners LLC bought a new stake in shares of Abiomed during the fourth quarter worth about $412,000. Franklin Resources Inc. grew its holdings in shares of Abiomed by 21.2% during the fourth quarter. Franklin Resources Inc. now owns 328,717 shares of the medical equipment provider’s stock worth $61,619,000 after purchasing an additional 57,560 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Abiomed by 59.8% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,415 shares of the medical equipment provider’s stock worth $453,000 after purchasing an additional 904 shares during the last quarter. Finally, Maverick Capital Ltd. bought a new stake in shares of Abiomed during the fourth quarter worth about $6,106,000. 88.02% of the stock is owned by hedge funds and other institutional investors.
ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; Impella CP that provides partial circulatory support using an extracorporeal bypass control unit; Impella 5.0 catheter and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter-based axial flow pump.
Receive News & Ratings for Abiomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abiomed and related companies with MarketBeat.com's FREE daily email newsletter.